Stephen E. Gitelman

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

Kevan C. Herold, William Hagopian, Julie Auger et al. · New England Journal of Medicine · 2002 · 1.2K citations · Full text

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Mark D. Pescovitz, Carla J. Greenbaum, Heidi Krause‐Steinrauf et al. · New England Journal of Medicine · 2009 · 1.1K citations · Full text

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Kevan C. Herold, Brian N. Bundy, S. Alice Long et al. · New England Journal of Medicine · 2019 · 1K citations · Full text

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch et al. · Science Translational Medicine · 2015 · 993 citations

Translational Medicine, Diabetes Management, Autoimmune Disease +13

A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

Kevan C. Herold, Stephen E. Gitelman, Umesh Masharani et al. · Diabetes · 2005 · 631 citations · Full text